Zacks Investment Research upgraded shares of Kadmon Holdings, Inc. (NYSE:KDMN) from a sell rating to a hold rating in a report released on Tuesday.
According to Zacks, “Kadmon Holdings, Inc. is a biopharmaceutical company. It engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of significant unmet medical need. The company is developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases. Kadmon Holdings, Inc. is headquartered in New York. “
A number of other research analysts have also recently commented on KDMN. ValuEngine cut Kadmon Holdings from a sell rating to a strong sell rating in a research note on Tuesday, August 1st. Piper Jaffray Companies set a $7.00 price objective on Kadmon Holdings and gave the stock a buy rating in a research note on Wednesday, August 2nd. WBB Securities cut Kadmon Holdings from a hold rating to a sell rating and set a $3.00 price target on the stock. in a research note on Monday, October 9th. Finally, HC Wainwright reiterated a buy rating and issued a $25.00 price target on shares of Kadmon Holdings in a research note on Friday, November 17th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the stock. Kadmon Holdings presently has an average rating of Hold and a consensus target price of $9.75.
Kadmon Holdings (NYSE:KDMN) last issued its quarterly earnings data on Thursday, November 9th. The company reported ($0.42) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.38) by ($0.04). The business had revenue of $2.28 million during the quarter, compared to the consensus estimate of $5.69 million. Kadmon Holdings’s quarterly revenue was down 60.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($4.24) EPS. research analysts predict that Kadmon Holdings will post -1.61 EPS for the current year.
TRADEMARK VIOLATION WARNING: This report was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://sportsperspectives.com/2017/11/24/kadmon-holdings-inc-kdmn-raised-to-hold-at-zacks-investment-research.html.
In related news, major shareholder Goldentree Asset Management Lp sold 302,950 shares of the business’s stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $2.73, for a total value of $827,053.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 8.41% of the company’s stock.
A number of institutional investors have recently made changes to their positions in the stock. Susquehanna International Group LLP increased its holdings in Kadmon Holdings by 3,211.2% in the third quarter. Susquehanna International Group LLP now owns 443,135 shares of the company’s stock valued at $1,485,000 after buying an additional 429,752 shares during the last quarter. Crestline Management LP bought a new stake in Kadmon Holdings in the third quarter valued at about $2,011,000. Old West Investment Management LLC bought a new stake in Kadmon Holdings in the third quarter valued at about $169,000. Wells Fargo & Company MN increased its holdings in Kadmon Holdings by 23.2% in the third quarter. Wells Fargo & Company MN now owns 73,956 shares of the company’s stock valued at $247,000 after buying an additional 13,923 shares during the last quarter. Finally, Sphera Funds Management LTD. bought a new stake in Kadmon Holdings in the third quarter valued at about $3,685,000. 27.96% of the stock is owned by hedge funds and other institutional investors.
About Kadmon Holdings
Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kadmon Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.